SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van KampenView Slideset
MSMaria SantoroPhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria SantoroView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander ThielenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca LombardiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le HingratView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Influence of resistance in the future- Richard Harrigan, MDView Slideset
PCPep CollMDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018The current status of PrEP in Europe- Pep Coll, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms- Stephanie PoppingView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assaysing next-generation sequencing- Robert EhretView Slideset
